CSL Licenses Novozymes’ Albumin Fusion Technology for Extending Protein Half-life
Novozymes (Bagsvaerd, Denmark) has signed an exclusive worldwide licensing agreement for its albumin fusion technology, albufuse, with CSL Behring (King of Prussia, PA).
Novozymes (Bagsvaerd, Denmark) has signed an exclusive worldwide licensing agreement for its albumin fusion technology, albufuse, with CSL Behring (King of Prussia, PA). Albufuse technology has been proven to extend the circulatory half-life of therapeutic proteins through genetic fusion to recombinant human albumin. The license will enable CSL Behring to use albufuse technology for research, development, and commercialization of novel biotherapeutic products.
CSL Behring has chosen albufuse technology because it has been shown to increase the circulatory half-life of a wide range of therapeutically relevant proteins, leading to increased bioavailability and therefore less frequent administration. The combined expression and production process eliminates the need for additional post-production chemical derivatization, such as PEGylation. Pre-clinical studies have demonstrated albufuse efficacy with a number of therapeutically relevant proteins.
Pre-clinical data presented at the American Society of Hematology 49th Annual Meeting and Exposition suggests that fusion of Factor VIIa (FVIIa) to recombinant human albumin, using albufuse, significantly extends the circulatory half-life of the protein. In the study, the fusion protein (rVIIa-FP) was shown to extend the half-life of the recombinant protein six-to-nine-fold compared to the wild type (rFVIIa). Additionally, rVIIa-FP demonstrated a biologic activity comparable to wild type rFVIIa. Recombinant factor VIIa (rFVIIa) is used to control bleeding episodes in hemophilia patients.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
